{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:12:49Z","timestamp":1780791169591,"version":"3.54.1"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jid.2024.07.021","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T12:24:11Z","timestamp":1723119851000},"page":"812-820.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["PCSK9 Inhibitors and the Risk of Vitiligo: A Mendelian Randomization Study"],"prefix":"10.1016","volume":"145","author":[{"given":"Tae-Jong","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Yeop","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghyuk","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Gyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Oh","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Seung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Hwa","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2024.07.021_bib1","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/jid.2014.529","article-title":"Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo","volume":"135","author":"Agarwal","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.07.021_bib2","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.jid.2017.03.020","article-title":"CXCL12 as a predictor of vitiligo activity and disease progression","volume":"137","author":"Alexeev","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.07.021_bib3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4274\/balkanmedj.2016.1005","article-title":"Increased risk of metabolic syndrome in patients with vitiligo","volume":"34","author":"Ata\u015f","year":"2017","journal-title":"Balkan Med J"},{"key":"10.1016\/j.jid.2024.07.021_bib4","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/pcmr.12941","article-title":"Support for increased cardiovascular risk in non-segmental vitiligo among Egyptians: a hospital-based, case-control study","volume":"34","author":"Azzazi","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jid.2024.07.021_bib5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J\u00a0R Stat Soc Series B Stat Methodol"},{"key":"10.1016\/j.jid.2024.07.021_bib6","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.4172\/2376-0427.1000239","article-title":"CCN3 and CCN5, new factors associated with skin pigmentation","volume":"3","author":"Brassie","year":"2016","journal-title":"Pigment Disord"},{"key":"10.1016\/j.jid.2024.07.021_bib7","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1080\/03610926.2015.1006778","article-title":"Estimating and contextualizing the attenuation of odds ratios due to non collapsibility","volume":"46","author":"Burgess","year":"2017","journal-title":"Commun Stat Theory Methods"},{"key":"10.1016\/j.jid.2024.07.021_bib8","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jid.2017.01.020","article-title":"Simvastatin protects human melanocytes from H2O2-induced oxidative stress by activating Nrf2","volume":"137","author":"Chang","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.07.021_bib9","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/ijd.14055","article-title":"Comorbidities in vitiligo: comprehensive review","volume":"57","author":"Dahir","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jid.2024.07.021_bib10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2024.07.021_bib11","first-page":"136","article-title":"Repatha (Evolocumab): second PCSK9 inhibitor approved by the FDA for patients with familial hypercholesterolemia","volume":"9","author":"Fala","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.jid.2024.07.021_bib12","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3389\/fimmu.2018.02449","article-title":"Asparaginyl endopeptidase (legumain) supports human Th1 induction via cathepsin L-mediated intracellular C3 activation","volume":"9","author":"Freeley","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.07.021_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/1744666X.2022.2017281","article-title":"The role of PCSK9 in inflammation, immunity, and autoimmune diseases","volume":"18","author":"Frosteg\u00e5rd","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jid.2024.07.021_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13075-020-02386-7","article-title":"Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with Anti-TNF-\u03b1: potential underlying mechanisms","volume":"23","author":"Frosteg\u00e5rd","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jid.2024.07.021_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.12688\/wellcomeopenres.16544.1","article-title":"Mendelian randomization for studying the effects of perturbing drug targets","volume":"6","author":"Gill","year":"2021","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.jid.2024.07.021_bib16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41586-021-04064-3","article-title":"The power of genetic diversity in genome-wide association studies of lipids [published correction appears in Nature 2023;618:E19\u201320]","volume":"600","author":"Graham","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jid.2024.07.021_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1214\/ss\/1009211805","article-title":"Confounding and collapsibility in causal inference","volume":"14","author":"Greenland","year":"1999","journal-title":"Statist Sci"},{"key":"10.1016\/j.jid.2024.07.021_bib18","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1111\/ijd.15330","article-title":"Simvastatin in vitiligo: an update with recent review of the literature","volume":"60","author":"Hasan","year":"2021","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jid.2024.07.021_bib19","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34408","article-title":"The MR-Base platform supports systematic causal inference across the human phenome","volume":"7","author":"Hemani","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.jid.2024.07.021_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/2277-9175.203159","article-title":"A\u00a0comparison of betamethasone valerate 0.1% cream twice daily plus oral simvastatin versus betamethasone valerate 0.1% cream alone in the treatment of vitiligo patients","volume":"6","author":"Iraji","year":"2017","journal-title":"Adv Biomed Res"},{"key":"10.1016\/j.jid.2024.07.021_bib21","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/ng.3680","article-title":"Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants","volume":"48","author":"Jin","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2024.07.021_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-0625.1993.tb00023.x","article-title":"Review of the etiopathomechanism of vitiligo: a convergence theory","volume":"2","author":"Le Poole","year":"1993","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2024.07.021_bib23","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0961203320926253","article-title":"Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus","volume":"29","author":"Liu","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.jid.2024.07.021_bib24","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1109\/TCBB.2018.2835459","article-title":"A\u00a0parametric targetability evaluation approach for vitiligo proteome extracted through integration of gene ontologies and protein interaction topologies","volume":"16","author":"Malhotra","year":"2019","journal-title":"IEEE\/ACM Trans Comput Biol Bioinform"},{"key":"10.1016\/j.jid.2024.07.021_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1251127","article-title":"FCRL1 immunoregulation in B cell development and malignancy","volume":"14","author":"Mamidi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.07.021_bib26","first-page":"28","article-title":"Alirocumab (Praluent): first in the new class of PCSK9 inhibitors","volume":"41","author":"Manniello","year":"2016","journal-title":"P\u00a0T"},{"key":"10.1016\/j.jid.2024.07.021_bib27","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s13555-020-00447-y","article-title":"Vitiligo, from physiopathology to emerging treatments: a review","volume":"10","author":"Migayron","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jid.2024.07.021_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-3-7","article-title":"Positive pleiotropic effects of HMG-CoA Reductase Inhibitor on vitiligo","volume":"3","author":"No\u00ebl","year":"2004","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jid.2024.07.021_bib29a","doi-asserted-by":"crossref","first-page":"449","DOI":"10.12688\/wellcomeopenres.19995.2","article-title":"MendelianRandomization v0.9.0: updates to an R package for performing Mendelian randomization analyses using summarized data","volume":"8","author":"Patel","year":"2023","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.jid.2024.07.021_bib29","first-page":"19","article-title":"Hepato-splenic and lipid profile abnormalities--do they exist in children affected with vitiligo?","volume":"22","author":"Pietrzak","year":"2014","journal-title":"Acta Dermatovenerol Croat"},{"key":"10.1016\/j.jid.2024.07.021_bib30","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jid.2016.12.028","article-title":"Misbalanced CXCL12 and CCL5 chemotactic signals in vitiligo onset and progression","volume":"137","author":"Rezk","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.07.021_bib31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1600-0625.2012.01473.x","article-title":"Study of CCN3 (NOV) and DDR1 in normal melanocytes and vitiligo skin","volume":"21","author":"Ricard","year":"2012","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2024.07.021_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","article-title":"New discoveries in the pathogenesis and classification of vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.07.021_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20975904","article-title":"Proprotein convertase subtilisin\/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus","volume":"12","author":"S\u00e1nchez-P\u00e9rez","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jid.2024.07.021_bib34","doi-asserted-by":"crossref","first-page":"a038984","DOI":"10.1101\/cshperspect.a038984","article-title":"Multivariable Mendelian randomization and mediation","volume":"11","author":"Sanderson","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jid.2024.07.021_bib35","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jeconom.2015.06.004","article-title":"A\u00a0weak instrument [Formula: see text]-test in linear IV models with multiple endogenous variables","volume":"190","author":"Sanderson","year":"2016","journal-title":"J\u00a0Econom"},{"key":"10.1016\/j.jid.2024.07.021_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13109","article-title":"Efficacy and safety of basic fibroblast growth factor (bFGF) related decapeptide solution plus tacrolimus 0.1% ointment versus tacrolimus 0.1% ointment in the treatment of stable vitiligo","volume":"32","author":"Shah","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.07.021_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15969","article-title":"Simvastatin and non-segmental vitiligo: a new potential treatment option?","volume":"35","author":"Shaker","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.07.021_bib38","article-title":"The safety and effectiveness of decapeptide in patients with vitiligo: a real-world study","volume":"15","author":"Sharma","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jid.2024.07.021_bib39","first-page":"2783","article-title":"Association of metabolic syndrome with vitiligo- a case control study","volume":"8","author":"Sinha","year":"2019","journal-title":"J\u00a0Evol Med Dent Sci"},{"key":"10.1016\/j.jid.2024.07.021_bib40","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/jdv.19451","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force part 1: towards a new management algorithm","volume":"37","author":"van Geel","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2024.07.021_bib41","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/aje\/kwq332","article-title":"Odds ratios for mediation analysis for a dichotomous outcome","volume":"172","author":"Vanderweele","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jid.2024.07.021_bib42","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jaad.2016.06.015","article-title":"A\u00a0double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo","volume":"76","author":"Vanderweil","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.07.021_bib43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2005.10.015","article-title":"Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages","volume":"188","author":"Veillard","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jid.2024.07.021_bib44","article-title":"Vitiligo: the association with metabolic syndrome and the role of simvastatin as an immunomodulator","volume":"13","author":"Verma","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.jid.2024.07.021_bib45","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2340\/00015555-0161","article-title":"Basic fibroblast growth factor promotes melanocyte migration via increased expression of p125(FAK) on melanocytes","volume":"86","author":"Wu","year":"2006","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2024.07.021_bib46","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/jim-2020-001390","article-title":"Efficacy and safety of oral simvastatin in the treatment of patients with vitiligo","volume":"69","author":"Zhang","year":"2021","journal-title":"J\u00a0Investig Med"},{"key":"10.1016\/j.jid.2024.07.021_bib47","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamadermatol.2022.6051","article-title":"Association of lipid-lowering drugs with risk of psoriasis: a Mendelian randomization study","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2024.07.021_bib48","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A\u00a0global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jid.2024.07.021_bib49","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/gepi.21965","article-title":"Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator","volume":"40","author":"Bowden","year":"2016","journal-title":"Genet Epidemiol"},{"key":"10.1016\/j.jid.2024.07.021_bib50","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression","volume":"44","author":"Bowden","year":"2015","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jid.2024.07.021_bib51","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/gepi.21758","article-title":"Mendelian randomization analysis with multiple genetic variants using summarized data","volume":"37","author":"Burgess","year":"2013","journal-title":"Genet Epidemiol"},{"key":"10.1016\/j.jid.2024.07.021_bib52","doi-asserted-by":"crossref","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.3","article-title":"Guidelines for performing Mendelian randomization investigations: update for summer 2023","volume":"4","author":"Burgess","year":"2023","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.jid.2024.07.021_bib53","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/sim.6835","article-title":"Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods","volume":"35","author":"Burgess","year":"2016","journal-title":"Stat Med"},{"key":"10.1016\/j.jid.2024.07.021_bib54","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41467-019-14156-4","article-title":"A\u00a0robust and efficient method for Mendelian randomization with hundreds of genetic variants","volume":"11","author":"Burgess","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2024.07.021_bib55","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/aje\/kwu283","article-title":"Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects","volume":"181","author":"Burgess","year":"2015","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jid.2024.07.021_bib56","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.biopsych.2023.01.027","article-title":"Metabolomic investigation of major depressive disorder identifies a potentially causal association with polyunsaturated fatty acids","volume":"94","author":"Davyson","year":"2023","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jid.2024.07.021_bib57","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41586-023-06563-x","article-title":"Large-scale plasma proteomics comparisons through genetics and disease associations [published correction appears in Nature 2024;630:E3]","volume":"622","author":"Eldjarn","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jid.2024.07.021_bib58","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1093\/bioinformatics\/btu367","article-title":"RAREMETAL: fast and powerful meta-analysis for rare variants","volume":"30","author":"Feng","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jid.2024.07.021_bib59","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41588-021-00978-w","article-title":"Large-scale integration of the plasma proteome with genetics and disease","volume":"53","author":"Ferkingstad","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2024.07.021_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/gepi.22506","article-title":"Statistical methods for cis-Mendelian randomization with two-sample summary-level data","volume":"47","author":"Gkatzionis","year":"2023","journal-title":"Genet Epidemiol"},{"key":"10.1016\/j.jid.2024.07.021_bib61","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41586-021-04064-3","article-title":"The power of genetic diversity in genome-wide association studies of lipids","volume":"600","author":"Graham","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jid.2024.07.021_bib62","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/ije\/dyx102","article-title":"Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption","volume":"46","author":"Hartwig","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jid.2024.07.021_bib63","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/ng.3680","article-title":"Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants","volume":"48","author":"Jin","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2024.07.021_bib64","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ajhg.2023.02.014","article-title":"Robust multivariable Mendelian randomization based on constrained maximum likelihood","volume":"110","author":"Lin","year":"2023","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jid.2024.07.021_bib65","doi-asserted-by":"crossref","first-page":"449","DOI":"10.12688\/wellcomeopenres.19995.2","article-title":"MendelianRandomization v0.9.0: updates to an R package for performing Mendelian randomization analyses using summarized data","volume":"8","author":"Patel","year":"2023","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.jid.2024.07.021_bib66","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1002\/sim.7492","article-title":"Extending the MR-Egger method for multivariable Mendelian randomization to correct for both measured and unmeasured pleiotropy","volume":"36","author":"Rees","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.jid.2024.07.021_bib67","doi-asserted-by":"crossref","first-page":"a040501","DOI":"10.1101\/cshperspect.a040501","article-title":"Mendelian randomization: concepts and scope","volume":"12","author":"Richmond","year":"2022","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jid.2024.07.021_bib68","doi-asserted-by":"crossref","first-page":"a038984","DOI":"10.1101\/cshperspect.a038984","article-title":"Multivariable Mendelian randomization and mediation","volume":"11","author":"Sanderson","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jid.2024.07.021_bib69","first-page":"1","article-title":"Mendelian randomization","volume":"2","author":"Sanderson","year":"2022","journal-title":"Nat Rev Methods Prim"},{"key":"10.1016\/j.jid.2024.07.021_bib70","first-page":"1","volume":"32","author":"Smith","year":"2003"},{"key":"10.1016\/j.jid.2024.07.021_bib71","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0749.2006.00355.x","article-title":"The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force","volume":"20","author":"Ta\u00efeb","year":"2007","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.jid.2024.07.021_bib72","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/biom.13732","article-title":"A\u00a0novel penalized inverse-variance weighted estimator for Mendelian randomization with applications to COVID-19 outcomes","volume":"79","author":"Xu","year":"2023","journal-title":"Biometrics"},{"key":"10.1016\/j.jid.2024.07.021_bib73","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.ajhg.2021.05.014","article-title":"Constrained maximum likelihood-based Mendelian randomization robust to both correlated and uncorrelated pleiotropic effects","volume":"108","author":"Xue","year":"2021","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jid.2024.07.021_bib74","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1214\/20-AOS2027","article-title":"Debiased inverse-variance weighted estimator in two-sample summary-data Mendelian randomization","volume":"49","author":"Ye","year":"2021","journal-title":"Ann Statist"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24019857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24019857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T01:54:29Z","timestamp":1775008469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X24019857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0022202X24019857"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2024.07.021","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PCSK9 Inhibitors and the Risk of Vitiligo: A Mendelian Randomization Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2024.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Society for Investigative Dermatology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}